Kymera Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $10.61B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $65.00M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $34.40M | $-0.71 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $2.90M | $-0.97 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $2.80M | $-0.94 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | $11.50M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | Before market open | $22.10M | $-0.82 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 14, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | Before market open | $3.70M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | $25.70M | $-0.58 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Press releases
Announcements Kymera Therapeutics filed with the SEC
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Agenda Introduction Justine Koenigsberg Vice President, Investor
Regulation FD disclosure · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
GILEAD SCIENCES AND KYMERA THERAPEUTICS ENTER
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Volunteer Results Revolutionizing Immunology with Oral Small Molecule Degrader Medicines
Regulation FD disclosure · EX-99.1 to Form 8-K
First-in-Human Results from Phase 1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Kymera Therapeutics Announces First Quarter 2025 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Nello Mainolfi, Ph.D., Founder, President and CEO J.P. Morgan Healthcare Conference January 2025
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Pricing of $225 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Proposed Public Offering
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
KYMERA THERAPEUTICS, INC. PAGE 1
Regulation FD disclosure · EX-99.1 to Form 8-K
R&D Day Highlights Kymeras Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Kymera Therapeutics Announces First Quarter 2023 Financial Results and
Results of operations · EX-99 to Form 8-K